Activist investor Bluebell Capital has built a stake in Bayer and is pushing the company to break up crop science unit from its pharmaceutical business, according to Bloomberg’s Crystal Tse, Swetha Gopinath and Aaron Kirchfeld, citing sources. Bluebell is also seeking an overhaul of the German company’s corporate governance, according to the report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAYRY: